What we do Glenmark Pharmaceuticals Ltd is a global pharmaceutical company engaged in discovery, development, manufacture, and marketing of generic and innovative medicines across key therapies like oncology, respiratory, and dermatology. |
Founded in 1,977 |
Market share Ranks 2nd in Dermatology, 2nd in Respiratory and 4th in Cardiac segments in India with expanding global presence across Americas, Europe, and emerging markets. |
Problem solved Provides affordable generic and innovative medicines addressing chronic diseases like cancer, respiratory disorders, diabetes, and dermatological conditions worldwide. |
Top clients or who we serve Serves patients globally via branded generics and innovative drugs focusing on B2B and B2C models, especially in India, North America, Europe, and emerging markets. |
Key management Glenn Saldanha (Chairman & Managing Director), V.S. Mani (Executive Director & Global CFO), notable leadership with global pharmaceutical experience. |
Our journey and innovations Founded in 1977, expanded globally with multiple manufacturing units; blends generics and novel drug discovery including India's first nebulized triple therapy for COPD. |
Where we operate Operations across India, USA, Europe, Latin America, Asia-Pacific, Middle East and Africa with products in over 90 countries worldwide. |
Top products or what we offer Branded generics, innovative oncology drugs, respiratory therapies including Ryaltris and Winlevi, and novel biologics in development pipeline. |
Top brands Ryaltris (allergic rhinitis), Winlevi (dermatology), Tevimbria and Brukinsa (oncology), Ashlyna (contraceptive), Momate (nasal sprays) – all market-accepted and growing. |
Raw materials needed Active pharmaceutical ingredients for drug formulations including chemical and biotech raw materials from global suppliers. |
Raw materials supplier Supplies mainly sourced through Glenmark Life Sciences and third-party global API vendors across regulatory markets. |
Recurring vs cyclical contribution Revenue driven by a mix of recurring generics sales and cyclical innovative drug approvals and launches. |
Our industry position Strong in Indian branded generics; expanding presence in regulated markets with approved ANDAs and licensed novel therapies globally. |
Financial highlights Consolidated Revenue ~Rs.118,131 million; EBITDA Rs.8,697 million (Q3 FY26); strong double-digit growth in core markets; consistent R&D investments. |
Geographical revenue split India 37.9%, North America 25.5%, Europe 25.4%, Rest of World 23.7% (approximate for FY2025-26, revenues in Rs. million). |
Order book Multiple ANDA filings pending globally with approvals and launches in pipeline; licensing agreements expand revenue visibility in oncology and respiratory. |
Whats driving growth Innovation in oncology and respiratory, strong generics portfolio, expanded manufacturing capacity, regulatory approvals, and geographic market expansions. |
Our future plans Focus on expanding innovative pipeline, manufacturing expansions, and new product launches globally, especially in oncology and respiratory therapy areas. |
Our green promise Committed to sustainability with energy conservation, waste reduction, and corporate social responsibility programs. |
Our people and values Diverse global workforce; emphasis on innovation, integrity, safety, and continuous professional development. |
Key challenges ahead Regulatory uncertainties, global competition, patent litigations, pricing pressures, and adaptation to evolving healthcare landscapes. |
Interesting facts First Indian pharma to launch nebulized fixed-dose triple COPD therapy; extensive global ANDA approvals over 370 DMFs filed worldwide. |
Risks and strategy Mitigates risks via diversified portfolio, compliance frameworks, strategic collaborations, and continuous R&D to sustain competitive advantage. |
